Results 1 to 1 of 1

Thread: FPGEE Blueprint

  1. #1
    Administrator admin's Avatar
    Join Date
    Jan 2013
    Location
    Chengdu, Sichuan, China
    Posts
    304

    Default FPGEE Blueprint

    The FPGEE Competency Statements serve as a blueprint of the topics covered on the examination. They offer important information about the knowledge, judgment, and skills you are expected to demonstrate while taking the FPGEE. A strong understanding of the Competency Statements will aid you in your preparation to take the examination.

    Competency Statements


    Area 1 - Basic Biomedical Sciences (16%)

    1A Physiology

    • 1A01 structure and function of major body systems; as it applies to integumentary, muscular skeletal, cardiovascular, lymphatic, respiratory, digestive, nervous, endocrine, urinary, reproductive, and body fluids and electrolytes, cells in tissue

    1B Biochemistry

    • 1B01 chemistry of biomacromolecules (proteins, lipids, carbohydrates, and DNA)
    • 1B02 nucleic acid biosynthesis and metabolism
    • 1B03 enzymology and coenzymes and kinetics
    • 1B04 metabolic pathways to energy utilization

    1C Microbiology

    • 1C01 general principles of microbial concepts
    • 1C02 principles of infectious diseases
    • 1C03 host-parasite relationships
    • 1C04 pathogenic microorganisms of man
    • 1C05 inflammatory responses to infectious agents

    1D Molecular Cell Biology/Genetics

    • 1D01 gene expression
    • 1D02 carrier proteins/membrane transport
    • 1D03 mechanics of cell division
    • 1D04 ion channels and receptor physiology
    • 1D05 chromosomes and DNA
    • 1D06 gene transcription and translation processes
    • 1D07 recombinant DNA technology

    1E Immunology

    • 1E01 human immunity and immune responses
    • 1E02 principles of antigen-antibody relationships
    • 1E03 antibody synthesis, development, function, and immunopathology

    Area 2 – Pharmaceutical Sciences (30%)

    2A Medicinal Chemistry

    • 2A01 physiochemical properties of drugs in relation to drug absorption, distribution, metabolism, and excretion (ADME)
    • 2A02 chemical basis for drug action
    • 2A03 fundamental pharmacophores for drugs used to treat diseases
    • 2A04 structure activity relationships in relation to drug-target interactions
    • 2A05 chemical pathways of drug metabolism
    • 2A06 applicability to making drug therapy decisions

    2B Pharmacology and Toxicology

    • 2B01 mechanisms of action of drugs of various categories
    • 2B02 pharmacodynamics of drug action and absorption, distribution, metabolism, and elimination
    • 2B03 adverse effects and side-effects of drugs
    • 2B04 drug-target interactions
    • 2B05 drug discovery and development
    • 2B06 mechanism of toxicity and toxicokinetics
    • 2B07 acute and chronic toxic effect of xenobiotics, including drug and chemical overdose and toxic signs of drugs of abuse
    • 2B08 interpretation of drug screens
    • 2B09 principles of antidotes and alternative approaches to toxic exposures
    • 2B10 functions of poison control centers
    • 2B11 bioterrorism and disaster preparedness and management

    2C Pharmacognosy and Alternative and Complementary Treatments

    • 2C01 concepts of crude drugs, semi-purified, and purified natural products
    • 2C02 evaluation of alternative and complementary medicine purity, bioavailability, safety, and efficacy
    • 2C03 classes of pharmacologically active natural products
    • 2C04 Science of dietary supplements (vitamins, minerals, and herbals)
    • 2C05 Dietary Health Supplement and Education Act and Impact on regulation of dietary supplements and herbal products

    2D Pharmaceutics

    • 2D01 physiochemical principles of dosage forms
    • 2D02 principles of drug delivery via dosage forms (eg, liquid, solid, semi-solid, controlled release, patches, and implants)
    • 2D03 principles of dosage form stability and drug degradation in dosage forms
    • 2D04 materials and methods used in preparation and use of drug forms

    2E Biopharmaceutics/Pharmacokinetics

    • 2E01 biological principles of dosage forms
    • 2E02 basic principles of in vivo drug kinetics (linear and nonlinear)
    • 2E03 principles of bioavailability/bioequivalence
    • 2E04 physiologic determinates of drug onset and duration
    • 2E05 drug, disease, and dietary influences on absorption, distribution, metabolism, and excretion
    • 2E06 the pharmacokinetic-pharmacodynamic interface

    2F Pharmacogenomics

    • 2F01 genetic basis for disease and drug action
    • 2F02 genetic basis for alteration and drug metabolism
    • 2F03 genome and proteomic principles in relation to disease and drug development
    • 2F04 genetic basis for individualizing drug doses

    2G Extemporaneous Compounding/Parenteral/Enteral

    • 2G01 United States Pharmacopeia guidance on compounding and FDA regulation of compounding
    • 2G02 techniques and principles used to prepare and dispense individual extemporaneous prescriptions including dating of compounded dosage forms
    • 2G03 extemporaneous liquid (parenteral, enteral), solid, semi-solid, and topical preparations
    • 2G04 dosage form preparation calculations
    • 2G05 sterile admixture techniques
      • a United States Pharmacopeia (USP) requirements for sterile compounding
      • b stability and sterility testing and dating
      • c clean room requirements
      • d infusion devices and catheters

    Area 3 – Social/Behavioral/Administrative Sciences (22%)

    3A Health Care and Public Health Delivery Systems

    • 3A01 introduction to United States, state, and local health care delivery systems and their interfaces and how they compare to those in other industrialized countries
    • 3A02 social, political, and economic factors influencing the delivery of health care (including financing and reimbursement mechanisms, health disparities, reform, etc)
    • 3A03 pharmacy and health care organizations (private and public insurers of third party administration, pharmaceutical industry, managed care organizations, PBMs, etc)
    • 3A04 health policy development and evaluation
    • 3A05 importance of involvement in pharmacy organizational, regulatory, state, and federal issues
    • 3A06 conflict between medical care and public health
    • 3A07 contributions of public health efforts to health status improvements (infectious disease control, chronic disease preventions, demographics, and social and physical environmental factors, etc)

    3B Economics/Pharmacoeconomics

    • 3B01 use of pharmacoeconomic analyses (ie, cost-benefit analysis, cost-effectiveness analysis, cost-minimization analysis, cost-utility analysis)
    • 3B02 applications of economic, clinical, and humanistic outcomes to improve allocation of limited health care resources
    • 3B03 general macro and micro economic principles

    3C Pharmacy Management

    • 3C01 management principles (planning, organizing, directing, and controlling pharmacy resources) applied to various pharmacy practice setting and patient outcomes
    • 3C02 personnel management – including leadership
    • 3C03 managing goods and services (marketing, purchasing/inventory management, and merchandising)
    • 3C04 financial accounting
    • 3C05 risk management in pharmacy practice

    3D Pharmacoepidemiology

    • 3D01 application of epidemiological study designs to study drug use and outcomes in large populations
    • 3D02 data sources and analytic tools that provide an estimate of the probability of beneficial or adverse effects of medication use in large populations
    • 3D03 methods for continually monitoring unwanted effects and other safety-related aspects of medication use in large populations

    3E Pharmacy Law and Regulatory Affairs

    • 3E01 administrative, civil, and criminal liability
    • 3E02 a pharmacist’s responsibilities and limits under the law
    • 3E03 the authority, responsibilities, and operation of agencies and entities that administer laws and regulations related to prescription, and over-the-counter medications

    3F Biostatistics and Research Design

    • 3F01 commonly used experimental and observational study designs
    • 3F02 commonly used statistical tests and their appropriate application
    • 3F03 evaluation of statistical results including an understanding of statistical versus clinical significance

    3G Ethics

    • 3G01 principles of biomedical ethics
    • 3G02 ethical dilemmas in the delivery of patient-centered care, including
    • a conflicts of interest
    • b end-of-life decision making
    • c development, promotion, sales, prescription, and use of drugs
    • d working in groups
    • 3G03 research ethics
    • 3G04 professional behavior (ie, professionalism, code of ethics, oath of the pharmacist)

    3H Core Communication Concepts and Skills

    • 3H01 patient counseling skills including active listening and empathy
    • 3H02 assertiveness and problem-solving techniques, handling difficult situations – patients and other core providers
    • 3H03 interviewing techniques
    • 3H04 health literacy
    • 3H05 cultural competency

    3I Social and Behavioral Aspects encountered in Practice

    • 3I01 health, illness, and sick role behaviors
    • 3I02 principles of behavior modification
    • 3I03 patient adherence
    • 3I04 caregiving throughout the life cycle
    • 3I05 death and dying
    • 3I06 patients’ and other health care providers’ perceptions of pharmacists’ capabilities

    3J Medication Dispensing and Distribution Systems

    • 3J01 safe and effective preparation and dispensing of medications in all types of practice settings
    • 3J02 development and maintenance of patient medication profiles
    • 3J03 role of automation and technology
    • 3J04 continuous quality improvement programs or protocols in the medication-use process, including identification and prevention of medication errors and establishment of error reduction programs, technology of drug information retrieval for quality assurance

    Area 4 – Clinical Sciences (32%)

    4A Literature Evaluation – Practice Guidelines and Clinical Trials

    • 4A01 principles of clinical practice guidelines for various disease states and their interpretation in the clinical setting
    • 4A02 integration of core scientific and systems-based knowledge in patient care decisions
    • 4A03 reinforcement of basic science principles relative to drug treatment protocols and clinical practice guidelines
    • 4A04 evaluation of clinical trials that validate treatment usefulness

    4B Drug Information

    • 4B01 fundamentals of the practice of drug information
    • 4B02 application of drug information skills for delivery of medication therapy management
    • 4B03 the ability to judge the reliability of various sources of information

    4C Clinical Pathophysiology

    • 4C01 pathophysiology of disease states amenable to pharmacist intervention

    4D Clinical Pharmacokinetics/Pharmacogenomics

    • 4D01 clinical pharmacokinetics/pharmacogenomics of commonly used and low-therapeutic-index drugs
    • 4D02 clinical basis for individualizing drug therapy

    4E Clinical Prevention and Population Health

    • 4E01 promotion of wellness and nonpharmacologic therapies
    • 4E02 disease prevention and monitoring

    4F Medication Therapy Management - Patient Assessment, Clinical Pharmacology, and Therapeutics

    • 4F01 concepts of pharmacist-provided patient care and medication therapy management services
    • 4F02 importance of and techniques for obtaining a comprehensive patient history
    • 4F03 patient assessment (eg, inspection, palpation, percussion, auscultation), terminology, and the modifications caused by common disease states and drug therapy
    • 4F04 common clinical laboratory values and diagnostic tests and their clinical role
    • 4F05 OTC point-of-care testing devices (eg, glucometers, pregnancy tests, home testing for HbA1c, drug screening).
    • 4F06 false positive and false negative results
    • 4F07 therapeutic drug concentrations and their interpretation
    • 4F08 problem identification (eg, duplication dosage, drug interactions, dietary interactions, adverse drug reactions and interactions, frequency dosage form, indication mismatches) and resolution planning
    • 4F09 triage and referral skills
    • 4F10 designing of patient-centered, culturally relevant treatment plans
    • 4F11 application of evidence-based decision making to patient care
    • 4F12 nonprescription and dietary supplements
    • 4F13 drug monitoring for positive and negative outcomes (including drug induced disease)
    • 4F14 clinical management of drug toxicity and overdosage
    Last edited by admin; Fri 4th September '15 at 4:33pm.
    B.S. Pharm, West China School of Pharmacy, Class of 2007, Health System Pharmacist, RPh. Hematology, Infectious Disease. Chengdu, Sichuan, China.

    Blog: http://www.tomhsiung.com
    Facebook: http://www.facebook.com/TomHsiung
    Twitter: @TomHsiung
    Sina Microblog (Weibo): http://weibo.com/xiongliang0



Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •